GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...

The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

The FDA is elevating a recall from Philips related to one of its wearable outpatient heart monitors, used to help detect ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...

Yesterday, spots of pink could be spotted on the streets of San Francisco, and it wasn’t a coincidence. Members of the ...

Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...

Daiichi Sankyo is turning to the German city of Heidelberg for help developing antibodies. The Japanese pharma giant is ...

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...

After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have ...

Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell ...